TJ342B - Derivatives of 6-aryl pyrido Ä2,3-dÜ pyrimidines and naphthyridines pharmaceutical composition possess inhibiting effect of cellular proliferation pr ovoking protein tyrosine kinase and method of inhibiting cellular proliferation - Google Patents

Derivatives of 6-aryl pyrido Ä2,3-dÜ pyrimidines and naphthyridines pharmaceutical composition possess inhibiting effect of cellular proliferation pr ovoking protein tyrosine kinase and method of inhibiting cellular proliferation

Info

Publication number
TJ342B
TJ342B TJ97000469A TJ97000469A TJ342B TJ 342 B TJ342 B TJ 342B TJ 97000469 A TJ97000469 A TJ 97000469A TJ 97000469 A TJ97000469 A TJ 97000469A TJ 342 B TJ342 B TJ 342B
Authority
TJ
Tajikistan
Prior art keywords
cellular proliferation
inhibiting
naphthyridines
tyrosine kinase
protein tyrosine
Prior art date
Application number
TJ97000469A
Other languages
English (en)
Inventor
Clifton John Blankley
Annette Marian Doherty
James Marino Hamby
Robert Lee Panek
Mel Conrad Shroeder
Howard Daniel Hollis Owalter
Cleo Connolly
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/539,410 external-priority patent/US5733913A/en
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of TJ342B publication Critical patent/TJ342B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
TJ97000469A 1994-11-14 1995-11-13 Derivatives of 6-aryl pyrido Ä2,3-dÜ pyrimidines and naphthyridines pharmaceutical composition possess inhibiting effect of cellular proliferation pr ovoking protein tyrosine kinase and method of inhibiting cellular proliferation TJ342B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33905194A 1994-11-14 1994-11-14
US08/539,410 US5733913A (en) 1994-11-14 1995-11-06 6-Aryl pyrido 2,3-d! pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation

Publications (1)

Publication Number Publication Date
TJ342B true TJ342B (en) 2002-10-06

Family

ID=26991470

Family Applications (1)

Application Number Title Priority Date Filing Date
TJ97000469A TJ342B (en) 1994-11-14 1995-11-13 Derivatives of 6-aryl pyrido Ä2,3-dÜ pyrimidines and naphthyridines pharmaceutical composition possess inhibiting effect of cellular proliferation pr ovoking protein tyrosine kinase and method of inhibiting cellular proliferation

Country Status (25)

Country Link
US (1) US5952342A (cs)
EP (1) EP0790997B1 (cs)
CN (1) CN1085666C (cs)
AT (1) ATE190978T1 (cs)
AU (1) AU711426B2 (cs)
BG (1) BG63162B1 (cs)
CZ (1) CZ286160B6 (cs)
DE (1) DE69515898T2 (cs)
DK (1) DK0790997T3 (cs)
ES (1) ES2146782T3 (cs)
FI (1) FI971953L (cs)
GE (1) GEP20012444B (cs)
GR (1) GR3033439T3 (cs)
HU (1) HUT76853A (cs)
IL (1) IL115970A (cs)
MD (1) MD1861G2 (cs)
MX (1) MX9702245A (cs)
NO (1) NO308250B1 (cs)
NZ (1) NZ296456A (cs)
PL (1) PL181893B1 (cs)
PT (1) PT790997E (cs)
RU (1) RU2191188C2 (cs)
SK (1) SK281724B6 (cs)
TJ (1) TJ342B (cs)
WO (1) WO1996015128A2 (cs)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
DE69716916T2 (de) 1996-07-13 2003-07-03 Glaxo Group Ltd., Greenford Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
EP1806348A3 (en) * 1997-02-05 2008-01-02 Warner-Lambert Company LLC Pyrido [2, 3 -d] pyrimidines and 4-amino-primidines as inhibitors of cellular proliferation
ATE391719T1 (de) * 1997-02-05 2008-04-15 Warner Lambert Co Pyrido (2,3-d) pyrimidine und 4-amino-primidine als inhibitoren der zellulären proliferation
US6498163B1 (en) 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
KR20010023089A (ko) * 1997-08-20 2001-03-26 로즈 암스트롱, 크리스틴 에이. 트러트웨인 단백질 티로신 키나제 및 세포주기 키나제 매개의 세포증식 억제용 나프티리디논
AP2000001964A0 (en) * 1998-05-26 2000-12-31 Warner Lambert Co Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation.
EP1801112A1 (en) * 1998-05-26 2007-06-27 Warner-Lambert Company LLC Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
GB9822450D0 (en) * 1998-10-14 1998-12-09 Smithkline Beecham Plc Medicaments
GB9914486D0 (en) 1999-06-21 1999-08-18 Smithkline Beecham Plc Medicaments
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB9917406D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
CN1395578A (zh) * 2000-01-25 2003-02-05 沃尼尔·朗伯公司 吡啶并[2,3－d]嘧啶－2,7－二胺激酶抑制剂
ATE348826T1 (de) 2000-07-26 2007-01-15 Smithkline Beecham Plc Aminopiperidin chinoline und ihre azaisosteren analoga mit antibakterieller wirkung
BR0113628A (pt) * 2000-08-31 2003-07-01 Hoffmann La Roche 7-oxo-piridopirimidinas como inibidores de uma proliferação celular
US6506749B2 (en) 2000-08-31 2003-01-14 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (I)
US6518276B2 (en) * 2000-08-31 2003-02-11 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (II)
US20020119148A1 (en) * 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
AU2002251788A1 (en) * 2001-01-19 2002-08-12 Smithkline Beecham Corporation Novel compounds and uses thereof
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
CN100376571C (zh) 2001-02-12 2008-03-26 霍夫曼-拉罗奇有限公司 6-取代的吡啶并嘧啶类化合物
WO2002090360A1 (en) * 2001-05-10 2002-11-14 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
WO2003000011A2 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
EA007395B3 (ru) 2002-01-22 2018-02-28 Уорнер-Ламберт Компани Ллс 2-(ПИРИДИН-2-ИЛАМИНО)ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНЫ
AR038240A1 (es) 2002-01-29 2005-01-05 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion
WO2003064431A2 (en) 2002-01-29 2003-08-07 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
AU2003211594A1 (en) * 2002-03-05 2003-09-16 Eisai Co., Ltd. Antitumor agent comprising combination of sulfonamide-containing heterocyclic compound with angiogenesis inhibitor
PA8577501A1 (es) 2002-07-25 2004-02-07 Warner Lambert Co Inhibidores de quinasas
MXPA05001332A (es) 2002-08-06 2005-04-28 Hoffmann La Roche 6-alcoxi-pirido-pirimidinas como inhibidores de cinasa del map p-38.
US7098332B2 (en) * 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
TW200502236A (en) * 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
RU2263146C2 (ru) * 2003-07-10 2005-10-27 Михаил Викторович Разуменко Способ получения бактериофагов, специфично связывающихся с клетками-мишенями и предназначенных для терапевтических целей
PL1648889T3 (pl) * 2003-07-11 2009-03-31 Warner Lambert Co Sól izetionian selektywnego inhibitora CDK4
EP1685131B1 (en) 2003-11-13 2007-03-07 F. Hoffmann-La Roche AG Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
ATE481134T1 (de) 2004-01-21 2010-10-15 Univ Emory Zusammensetzungen und verwendung von tyrosinkinase-hemmern zur behandlung von pathogenen infektionen
RU2006136082A (ru) * 2004-03-15 2008-04-27 Ф.Хоффманн-Ля Рош Аг (Ch) Новые производныедихлорфенилпиридо[2,3]пиримидина, их получение и применение в качестве фармацевтических агентов
FR2873118B1 (fr) * 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
WO2006032452A1 (en) * 2004-09-21 2006-03-30 F. Hoffmann-La Roche Ag 6-(2-alkyl-phenyl) - pyrido[2,3-d] pyrimidines useful as proteine kinase inhibitors
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
EP1838296B1 (en) * 2004-10-20 2012-08-08 Resverlogix Corp. Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
WO2007060028A1 (en) * 2004-12-31 2007-05-31 Gpc Biotech Ag Napthyridine compounds as rock inhibitors
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
CA2617213C (en) 2005-07-29 2014-01-28 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
ES2351939T3 (es) 2005-08-09 2011-02-14 Irm Llc Compuestos y composiciones como inhibidores de proteínas cinasas.
US20070082920A1 (en) * 2005-10-06 2007-04-12 Yongsheng Song NAD+-dependent DNA ligase inhibitors
RU2445315C2 (ru) * 2005-11-22 2012-03-20 Кудос Фармасьютиклз Лимитед ПРОИЗВОДНЫЕ ПИРИДО-, ПИРАЗО- И ПИРИМИДО-ПИРИМИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
EP1981886B1 (en) 2006-01-31 2009-08-12 F.Hoffmann-La Roche Ag 7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
ES2366489T3 (es) 2006-09-15 2011-10-20 Pfizer Products Inc. Compuesto de pirido (2,3-d) piridinona y sus uso como inhibidores de pi3.
WO2008055842A1 (en) * 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Substituted 6-phenyl-pyrido [2,3-d] pyrimidin-7-one derivatives as kinase inhibitors and methods for using the same
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
SI2118074T1 (sl) 2007-02-01 2014-05-30 Resverlogix Corp. Spojine za preprečevanje in zdravljenje kardiovaskularnih bolezni
WO2008104473A2 (en) * 2007-02-28 2008-09-04 F. Hoffmann-La Roche Ag Pyrazolopyriidine derivatives and their use as kinase inhibitors
US20090203709A1 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
CA2747417C (en) 2009-01-08 2017-01-03 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
CA3146333A1 (en) 2009-03-18 2010-09-23 Resverlogix Corp. Phenyl-quinazolin-4(3h)-one and phenyl-pyrido[2,3-d]pyrimidin-4(3h)-one derivatives and compositions thereof useful as anti-inflammatory agents
MX352614B (es) 2009-04-22 2017-12-01 Resverlogix Corp Nuevos agentes anti-inflamatorios.
ES2347630B1 (es) * 2009-04-29 2011-09-08 Universitat Ramon Llull Sintesis y usos de 4-cianopentanoatos y 4-cianopentenoatos sustituidos.
GB0922589D0 (en) * 2009-12-23 2010-02-10 Almac Discovery Ltd Pharmaceutical compounds
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
WO2013064900A1 (en) 2011-11-01 2013-05-10 Resverlogix Corp. Oral immediate release formulations for substituted quinazolinones
KR102556118B1 (ko) 2012-06-13 2023-07-19 인사이트 홀딩스 코포레이션 Fgfr 억제제로서 치환된 트리사이클릭 화합물
PL2872491T3 (pl) * 2012-07-11 2021-12-13 Blueprint Medicines Corporation Inhibitory receptora czynnika wzrostu fibroblastów
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
KR20150096794A (ko) 2012-12-21 2015-08-25 제니쓰 에피제네틱스 코포레이션 브로모도메인 저해제로서의 신규한 헤테로사이클릭 화합물
EP3943087A1 (en) 2013-03-15 2022-01-26 Celgene CAR LLC Heteroaryl compounds and uses thereof
SG11201507478VA (en) * 2013-03-15 2015-10-29 Celgene Avilomics Res Inc Heteroaryl compounds and uses thereof
AR095464A1 (es) 2013-03-15 2015-10-21 Celgene Avilomics Res Inc Compuestos de heteroarilo y usos de los mismos
KR102469849B1 (ko) 2013-04-19 2022-11-23 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
CN110028491B (zh) 2013-10-25 2022-02-11 缆图药品公司 纤维母细胞生长因子受体抑制剂
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MX388991B (es) 2015-02-20 2025-03-20 Incyte Corp Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr)
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
JP6903585B2 (ja) 2015-03-13 2021-07-14 レスバーロジックス コーポレイション 補体関連疾患の治療のための組成物および治療方法
WO2016168331A1 (en) * 2015-04-14 2016-10-20 Eisai R&D Management Co., Ltd. Crystalline fgfr4 inhibitor compound and uses thereof
CN104774183B (zh) * 2015-04-24 2017-10-13 合肥新诺华生物科技有限公司 一种甲酰基瑞舒伐汀钙中间体的制备方法
WO2018023081A1 (en) * 2016-07-29 2018-02-01 Achaogen, Inc. 6-phenylpyrido[2,3-d]pyrimidine compounds as antibacterial agents
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
CA3097962A1 (en) 2018-04-23 2019-10-31 Kyoto University Growth inhibitor
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20220099958A (ko) * 2019-10-01 2022-07-14 골드핀치 바이오 인코포레이티드 Cdk5의 치환된 1,6-나프티리딘 억제제
CR20220169A (es) 2019-10-14 2022-10-27 Incyte Corp Heterociclos bicíclicos como inhibidores de fgfr
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171218A (en) * 1967-11-09 1969-11-19 Parke Davis & Co New Heterocyclic Amine Compounds and Methods for their Production
US3639401A (en) * 1969-07-28 1972-02-01 Parke Davis & Co 6-aryl-2 7-bis((trialkylsilyl)amino)pyrido (2 3-d)pyrimidine compounds
US4271164A (en) * 1979-04-16 1981-06-02 Warner-Lambert Company 6-Substituted-arylpyrido[2,3-d]pyrimidin-7-amines and derivatives
US4771054A (en) * 1985-01-23 1988-09-13 Warner-Lambert Company Antibacterial agents
US4771057A (en) * 1986-02-03 1988-09-13 University Of Alberta Reduced pyridyl derivatives with cardiovascular regulating properties
DK172753B1 (da) * 1988-05-25 1999-06-28 Lilly Co Eli N-(5,6,7,8-tetrahydropyrido[2,3--d]pyrimidin-6-yl-alkanoyl)-glutaminsyrederivater, deres anvendelse, farmaceutiske præparat
DE4131029A1 (de) * 1991-09-18 1993-07-29 Basf Ag Substituierte pyrido (2,3-d) pyrimidine als antidots

Also Published As

Publication number Publication date
GR3033439T3 (en) 2000-09-29
PT790997E (pt) 2000-06-30
MX9702245A (es) 1997-06-28
ATE190978T1 (de) 2000-04-15
SK60997A3 (en) 1998-05-06
FI971953A0 (fi) 1997-05-07
DE69515898D1 (de) 2000-04-27
IL115970A0 (en) 1996-01-31
MD970187A (en) 1999-02-28
NO972198D0 (no) 1997-05-13
EP0790997B1 (en) 2000-03-22
CZ286160B6 (cs) 2000-01-12
CZ139097A3 (cs) 1998-02-18
PL181893B1 (pl) 2001-10-31
NO972198L (no) 1997-05-13
HUT76853A (en) 1997-12-29
SK281724B6 (sk) 2001-07-10
BG63162B1 (bg) 2001-05-31
MD1861G2 (ro) 2002-09-30
AU4107896A (en) 1996-06-06
BG101326A (bg) 1998-04-30
FI971953A7 (fi) 1997-05-12
EP0790997A2 (en) 1997-08-27
NZ296456A (en) 1999-09-29
DK0790997T3 (da) 2000-08-21
WO1996015128A2 (en) 1996-05-23
DE69515898T2 (de) 2000-08-17
US5952342A (en) 1999-09-14
ES2146782T3 (es) 2000-08-16
MD1861F2 (en) 2002-02-28
CN1085666C (zh) 2002-05-29
NO308250B1 (no) 2000-08-21
RU2191188C2 (ru) 2002-10-20
CN1169726A (zh) 1998-01-07
FI971953L (fi) 1997-05-12
WO1996015128A3 (en) 1996-07-11
GEP20012444B (en) 2001-05-25
AU711426B2 (en) 1999-10-14
IL115970A (en) 1999-06-20
PL320169A1 (en) 1997-09-15

Similar Documents

Publication Publication Date Title
TJ342B (en) Derivatives of 6-aryl pyrido Ä2,3-dÜ pyrimidines and naphthyridines pharmaceutical composition possess inhibiting effect of cellular proliferation pr ovoking protein tyrosine kinase and method of inhibiting cellular proliferation
IL117923A0 (en) Pyrido [2,3-d] pyrimidine derivatives and pharmaceutical compositions containing them
AP9901435A0 (en) Bicycle heteroaromatic compounds as protein tyrosine kinase inhibitors.
CA2400554A1 (en) Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
MY141144A (en) 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
NO984199D0 (no) Nye N-7-heterocyklylpyrrolo[2,3-D]pyridiner og deres anvendelse
IL139599A0 (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
CA2315647A1 (en) Inhibition of p38 kinase activity using aryl and heteroaryl substituted heterocyclic ureas
BRPI0412993A (pt) inibidores da atividade da akt
TR199900049T2 (xx) Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler.
AU1783201A (en) 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
AU1781601A (en) 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
BG105003A (en) Combinations of protein farnesyltransfer and hmg coa reductase inhibitors and their use to treat cancer
CO4920227A1 (es) Histidina-n-bencil glicinamida sustituida con cicloalquilos .
ATE294802T1 (de) 3-alkylimidazopyridine
ES2036128A1 (es) Procedimiento para la preparacion de 4-(imidazo)1,5-a)piridin-8l)-1,4-dihidropiridinas.